Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

A new generic version of varenicline – originally sold in the UK as Champix by Pfizer – has now been approved for use by the ...

There is no main sponsor, as Bonmati said, although Liga F does have deals with Puma, Panini, GSK, Mahou, Solan de Cabra and ...

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

By restructuring our collaboration with GSK, we have embarked on a new chapter of growth and ... as well as co-heading European healthcare investments at 3i Group plc, a UK-listed private equity firm ...

The US group's division has reported a pre-tax profit of $39.5m (£30.6m) for the 12 months to 31 January, 2024, according to ...

From healthcare to banking, it is the software-of-choice for some of the biggest names in the UK market. Think AstraZeneca (AZN.L), GSK (GSK.L), Rolls-Royce (RR.L) and Lloyds (LLOY.L). Even the London ...

GlaxoSmithKline is reportedly close to finding a development partner for a major new investment project in the UK that will see a new bioscience cluster built near its research centre in Stevenage.

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 billion in ...